

**DATA SHEET**  
**Hsa-miR-125bProbe**

**Catalog NoDescription**

**HM125B-100**One vial of 0.650 ml of probe in hybridization buffer

**Analyte Specific Reagent. Analytical and performance characteristics are not established.**

---

Doc. No. 932-HM125B-100      Rev : D

Date of release: 11-Aug-2020

**Description**

The Hsa-miR-125bprobe has been designed from mature human miR-125b sequence. This fluoresceinated probe is provided in a hybridization buffer for localization of miRNA in FFPE tissue by *In Situ* hybridization.

**Specifications**

The Hsa-miR-125b identifies mature miR-125b sequences in formalin-fixed, paraffin-embedded human tissues and/or freshly prepared frozen tissues by *in situ* hybridization. This probe does not react with normal human mRNA or nuclear DNA present in tissues.

**Storage and Handling**

Store the reagent at 2-8 °C. Do not freeze. Do not use the reagent after expiration date on vial. The reagent must be brought to room temperature before use. (Important! The presence of precipitates induces background staining).

**Precautions:**

For professional use. The probe contains formamide. Formamide is classified as a teratogen. Pregnant workers should keep exposure to a minimum. Avoid inhalation, ingestion, and contact with unprotected skin. If skin contact occurs, wash thoroughly with soap and water. For more information, refer to the Material Safety Data Sheet, which is available upon request.

**Quality Control**

Each lot of this micro RNA probe is tested by *In Situ* hybridization for Quality Control purposes. Refer to the BioGenex Quality Control Testing Conditions table for additional information

**References**

1. Lorio MV and Croce CM. (2012). MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review. *EMBO Mol Med* 4, 143–159.
2. Chen PS, Su JL, and Hung MC. (2012). Dysregulation of Micro RNAs in cancer. *Journal of Biomedical Science*, 19:90.
3. Nuovo GJ. (2008). In situ detection of precursor and mature microRNAs in paraffin embedded, formalin fixed tissues and cell preparations. *Methods* 44,39–46.
4. Song R. et al. (2010). *In situ* hybridization detection of microRNAs. *Methods Mol Biol.* 629, 287-94.
5. Bloomston M, Frankel WL, Petrocca F, Volinia S, Alder H, Hagan JP, Liu CG, Bhatt D, Taccioli C, Croce CM: MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. *JAMA* 2007, 297:1901–1908
6. Jiang F. Liu et al., MiR-125b promotes proliferation and migration of type II endometrial carcinoma cells through targeting TP53INP1 tumor suppressor in vitro and in vivo. *BMC Cancer* 2011, 11:425
7. Marina Bousquet, Diu Nguyen, Cynthia Chen, Lauren Shields, and Harvey F. Lodish MicroRNA-125b transforms myeloid cell lines by repressing multiple mRNA haematologica 2012; 97(11) 1713-1721
8. ShiXB, Xue L, Ma AH, Tepper CG, Kung HJ, White RW: miR-125b promotes growth of prostate cancer xenograft tumor through targeting proapoptotic genes. *Prostate* 2011, 71: 538-549.

**BioGenex Quality Control Testing Conditions**

<b>Parameter</b>	<b>Conditions used</b>
Control Tissue	OVARY (FB-HM125B)
Tissue Type	Formalin-fixed, paraffin-embedded cancer tissues